NCT02439346 is a Phase 1 clinical trial of BAY1143269 tablet in Medical Oncology, sponsored by Bayer.

Who is sponsoring NCT02439346?

NCT02439346 is sponsored by Bayer.

What drugs are being tested in NCT02439346?

Interventions in NCT02439346: BAY1143269 tablet.

What condition does NCT02439346 study?

NCT02439346 studies Medical Oncology.

Is NCT02439346 still recruiting?

NCT02439346 is currently terminated. Last updated 7 March 2018.

Last reviewed 2018-03-07 · How we verify

NCT02439346

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

Terminated Phase 1 Last updated 7 March 2018

What this trial tests

Phase 1 trial testing BAY1143269 tablet in Medical Oncology in 15 participants. Terminated before completion.

Timeline

15 June 2015

Primary endpoint
27 March 2017

24 April 2017

Quick facts

Lead sponsor	Bayer
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	15 June 2015
Primary completion	27 March 2017
Estimated completion	24 April 2017
Sites	4 locations across United Kingdom, United States

Drugs / interventions tested

BAY1143269 tablet — full drug profile →

Conditions studied

Medical Oncology — all drugs for Medical Oncology →

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Medical Oncology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Translational Control in Cancer.
Robichaud N, Sonenberg N, Ruggero D, Schneider RJ. · · 2019 · cited 239× · PMID 29959193 · DOI 10.1101/cshperspect.a032896
Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain.
Yousuf MS, Shiers SI, Sahn JJ, Price TJ. · · 2021 · cited 51× · PMID 33203717 · DOI 10.1124/pharmrev.120.000030
Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer.
Pinto-Díez C, Ferreras-Martín R, Carrión-Marchante R, González VM, et al · · 2020 · cited 41× · PMID 32340135 · DOI 10.3390/ijms21082967
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.
Prabhu SA, Moussa O, Miller WH, Del Rincón SV. · · 2020 · cited 28× · PMID 32517051 · DOI 10.3390/ijms21114055
Targeting Protein Synthesis in Colorectal Cancer.
Schmidt S, Denk S, Wiegering A. · · 2020 · cited 23× · PMID 32455578 · DOI 10.3390/cancers12051298
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy.
Gitareja K, Chelliah SS, Sanij E, Sandhu S, et al · · 2025 · cited 6× · PMID 40805230 · DOI 10.3390/cancers17152534
Chemical Probes for Studying the Eukaryotic Translation Initiation Factor 4E (eIF4E)-Regulated Translatome in Cancer.
O'Rourke RL, Garner AL. · · 2025 · cited 5× · PMID 40109752 · DOI 10.1021/acsptsci.4c00674
Targeting protein synthesis pathways in MYC-amplified medulloblastoma.
Kumar D, Kanchan R, Chaturvedi NK. · · 2025 · cited 5× · PMID 39779613 · DOI 10.1007/s12672-025-01761-7

Verify or expand the search:

Other recruiting trials for Medical Oncology

Currently open trials in the same condition.

NCT06097533 — Improvement of Quality of Life by Cannabinoids in Oncologic Patients · Phase 2 · recruiting
NCT05359848 — A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemot · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02439346 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 7 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02439346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing